Categories Earnings, Other Industries

Arcadia Biosciences swings to profit in Q2

Arcadia Biosciences (NASDAQ: RKDA) swung to profit in the second quarter from a loss last year, helped by the change in the fair value of common stock warrant and common stock adjustment feature liabilities. The bottom line exceeded analysts’ expectations while the top line missed consensus estimates.

Net income was $4.24 million or $0.84 per share, compared to a loss of $6.67 million or $2.02 per share in the previous year quarter. Revenues dropped by 53% to $203,000, largely due to the result of the wind-down in government grant and contract research activity.

Over the next three to 12 months, as the company transitions to its new focus on health and nutrition quality products, Arcadia expects revenue from government grants and research contracts revenues to be replaced by product and trait revenues from wheat and hemp.

Arcadia Biosciences Q2 earnings review
Image for representation. Courtesy: Pete Linforth from Pixabay

The company said its focus for the rest of 2019 will be on continuing this momentum to achieve first revenues in wheat, soy, and hemp by the end of the year, positioning it to significantly scale revenues in 2020.

The company, which preponed its earnings release ahead of the market close, said it scaled up production of its GoodWheat specialty wheat varieties, harvesting winter trials with higher than expected yields. Summer production trials have been planted in key wheat growing areas. The company expects first sales of GoodWheat products by the end of the year.

Also read: Baidu Q2 earnings preview

Arcadia recently launched a strategic joint venture with Legacy Ventures Hawaii to grow, extract and sell superior sun-grown hemp. The result is one vertically integrated supply chain, from seed to sale, enabling Archipelago to deliver superior hemp extract. The company completed its first harvest in Hawaii and is now expanding production acres and establishing extraction capabilities. First sales of hemp products are expected by the end of the year, with a significant ramp up in 2020.

Also Read:  Marathon agrees to buy Andeavor for $23.3 billion

Verdeca, Arcadia’s joint venture with Bioceres Crop Solutions, received two key regulatory approvals for its HB4 drought and herbicide tolerant soybeans. Brazil approved the traits in late May, followed by the US Department of Agriculture approving the trait. This comes on heels two years after the approval by the US Food and Drug Administration. Initial sales will commence in Argentina, pending import approval from China, which is now expected in 2020.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Wayfair (W) stock looks less attractive despite low price, thanks to market selloff

Shareholders of online furniture retailer Wayfair Inc. (NYSE: W) have been speculating about their returns for long, with the stock not making any meaningful gains in the past several months.

Here’s how Chewy (CHWY) held its ground in a COVID-19 world

Shares of Chewy Inc. (NYSE: CHWY) were down 6% in afternoon hours on Friday, a day after the company reported a narrower-than-expected loss and sales that matched estimates for its

What to look for when Levi Strauss (LEVI) reports Q1 earnings on April 7

Levi Strauss & Co. (NYSE: LEVI) is slated to report its first-quarter 2020 earnings results on Tuesday, April 7, after the market closes. The bottom line will be impacted by